About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Jumbo Jet Crashes Killing All – So What

Imagine these headlines in your local newspaper: JUMBO JET CRASHES KILLING ALL – 1,000 PEOPLE DIE! The front pages of all of our newspapers would scream about this massive tragedy of “epic proportions.” Now imagine that that a jumbo jet crashes and kills everyone on board every two weeks for an entire year. Every two [...]

The FDA Launches a Web Site that Allows Us to Access Complete Drug Information

The FDA has launched a web site that is now available to both patients and health care professionals that gives complete access to the information on file about all adverse effects and drug safety concerns for all FDA approved prescription medications. The goal of the site is to consolidate all this information into one place [...]

Early Versus Deferred Androgen Suppression in the Treatment of Advanced Prostatic Cancer – Which Is Better?

An informative and comprehensive analysis of existing research studies evaluating the merits of early vs. deferred commencement of hormone therapy in men with advanced prostate cancer was recently published. The analysis (Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic [...]

Prominent Attorney with Terminal Cancer Gets Tysabri After Biogen Idec’s Earlier Denial- Its Implications for Prostate Cancer Treatment

A prominent attorney, Frederick Baron, who is dying of bone marrow cancer, has been granted his wish, to receive the drug Tysabri. After significant wrangling, The FDA and the Mayo Clinic found a legal basis to give him the drug in an emergency situation, even though Tysabri is not approved for any cancers. This decision [...]

Interim Phase II Results Support A Positive result Of CB7630 (Abiraterone Acetate) In Advanced Prostate Cancer Patients

Today, Cougar Biotechnology, Inc. (NASDAQ:CGRB) unveiled the results from its ongoing Phase II clinical trial drug CB7630 (abiraterone acetate). The data was presented at the Prostate Cancer Foundation Scientific Retreat in Lake Tahoe, Nevada. The clinical trial, which is centered at the M.D. Anderson Cancer Center in Texas and was designed to look at the [...]

Go to Top